Biospecimen s15-­01162

Multidimensional Approach to Understanding Cutaneous T-­cell Lymphoma

This is a non-­interventional multicenter human research study in which we hope to better understand genetic and epigenetic changes that take place in T cells in Cutaneous T-­cell lymphoma (CTCL).

Eligibility Criteria:

1. HPatients with a histologic diagnosis of a) newly diagnosed, b) progressive, or c) relapsed CTCL, or LYP who are initiating or changing therapy, including vorinostat or romidepsin.
2. Patients with Sezary Syndrome or stage IVB CTCL as defined by blood involvement on flow cytometry or morphology: (1) ≥1000/microL Sézary cells by morphology; (2) CD4/CD8 ratio ≥10; (3) CD4+CD7-­ cells ≥40 percent;; (4) or CD4+CD26-­ cells ≥30 percent.
3. Not have history of previous lymphoma other than CTCL or SS or LYP.
   

This study is for patients age 18 and older.

Available at: Hartford Hospital.